Patents by Inventor Robert David Willacy

Robert David Willacy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for preparing 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole
    Patent number: 10266525
    Abstract: The present invention provides novel processes for preparing compounds of formula (IV) and salts thereof novel intermediates, and a novel salt and polymorph thereof.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: April 23, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Robert Nicholas Bream, John David Hayler, Alan Geoffrey Ironmonger, Peter Szeto, Michael Robert Webb, Katherine Marie Penelope Wheelhouse, Robert David Willacy
  • NOVEL PROCESSES
    Publication number: 20180155334
    Abstract: The present invention provides novel processes for preparing compounds of formula (IV) and salts thereof novel intermediates, and a novel salt and polymorph thereof.
    Type: Application
    Filed: May 31, 2016
    Publication date: June 7, 2018
    Inventors: Robert Nicholas BREAM, John David HAYLER, Alan Geoffrey IRONMONGER, Peter SZETO, Michael Robert WEBB, Katherine Marie Penelope WHEELHOUSE, Robert David WILLACY
  • Novel Polymorphs and Salts
    Publication number: 20160237073
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 26, 2016
    Publication date: August 18, 2016
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Polymorphs and salts
    Patent number: 9353098
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 31, 2016
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Novel Polymorphs and Salts
    Publication number: 20150299177
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 22, 2015
    Inventors: Julie Nicole HAMBLIN, Paul Spencer JONES, Suzanne Elaine KEELING, Joelle LE, Charlotte Jane MITCHELL, Nigel James PARR, Robert David WILLACY
  • Polymorphs and salts
    Patent number: 9102668
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: August 11, 2015
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • 6-(1-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof
    Patent number: 8993576
    Abstract: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Glaxo Group Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr, Robert David Willacy
  • Novel Polymorphs and Salts
    Publication number: 20140256721
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: April 14, 2014
    Publication date: September 11, 2014
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Polymorphs and salts
    Patent number: 8735390
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: May 27, 2014
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Polymorphs and Salts
    Publication number: 20130203772
    Abstract: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 8, 2013
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Nigel James Parr, Robert David Willacy
  • Novel Polymorphs and Salts
    Publication number: 20130165441
    Abstract: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
    Type: Application
    Filed: September 6, 2011
    Publication date: June 27, 2013
    Applicant: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Julie Nicole Hamblin, Paul Spencer Jones, Suzanne Elaine Keeling, Joelle Le, Charlotte Jane Mitchell, Nigel James Parr, Robert David Willacy
  • Novel Processes
    Publication number: 20120220779
    Abstract: The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.
    Type: Application
    Filed: November 2, 2010
    Publication date: August 30, 2012
    Inventors: Claire Frances Crawford, Sandrine Garcia, Jonathan Paul Graham, Sandra Jane Harling, Nicholas Paul Henley, Stephen Andrew Hermitage, John Howard Hutchinson, Trevor Raymond Keel, Andrew Kennedy, Andrew McMurtrie Mason, Mark Simon Scott, Neil Michael Smith, Nicholas Simon Stock, Yuichi Tateno, Leontine Saskia Trouw, Peter Graham Turner, Christopher John Wallis, Robert David Willacy